Skip to main content

Table 3 Mean change from baseline in blood and iron parameters before and after IIM treatment

From: NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease

Parameter, by timepoint

≤1000 mg

(N = 198)

> 1000 mg

(N = 58)

Difference

(95% CI)

p-value

Hb, g/L

 After Course 1 (≤1000 mg, n = 194; > 1000 mg, n = 56)

6.58 (4.94, 8.21)

10.59 (7.52, 13.66)

4.02 (0.54, 7.50)

0.024

 Before Course 2 (≤1000 mg, n = 56; > 1000 mg, n = 10)

-0.26 (-3.61, 3.08)

4.96 (-2.96, 12.88)

5.22 (-3.40, 13.84)

0.231

 After Course 2 (≤1000 mg, n = 55; > 1000 mg, n = 7)

8.39 (4.63, 12.16)

7.79 (-2.85, 18.43)

-0.60 (-11.93, 10.73)

0.916

Ferritin, μg/L

 After Course 1 (≤1000 mg, n = 157; > 1000 mg, n = 43)

277.98 (238.50, 317.46)

306.09 (227.42, 384.75)

28.10 (-60.32, 116.53)

0.531

 Before Course 2 (≤1000 mg, n = 45; > 1000 mg, n = 7)

91.50 (55.12, 127.88)

120.25 (4.72, 235.77)

28.74 (-93.71, 151.19)

0.638

 After Course 2 (≤1000 mg, n = 42; > 1000 mg, n = 6)

458.23 (317.77, 598.70)

424.37 (-177.2, 1026.0)

-33.86 (-652.3, 584.61)

0.912

TSAT, %

 After Course 1 (≤1000 mg, n = 98; > 1000 mg, n = 31)

8.13 (5.86, 10.40)

9.90 (5.36, 14.45)

1.77 (-3.33, 6.87)

0.492

 Before Course 2 (≤1000 mg, n = 35; > 1000 mg, n = 7)

0.89 (-0.95, 2.74)

2.36 (-2.21, 6.94)

1.47 (-3.56, 6.49)

0.555

 After Course 2 (≤1000 mg, n = 26; > 1000 mg, n = 5)

14.89 (8.42, 21.35)

13.17 (-1.60, 27.94)

-1.72 (-18.18, 14.75)

0.830

Platelets, × 109/L

 After Course 1 (≤1000 mg, n = 127; > 1000 mg, n = 45)

-17.21 (-25.36, -9.06)

-25.75 (-39.47, -12.03)

-8.54 (-24.57, 7.49)

0.294

 Before Course 2 (≤1000 mg, n = 47; > 1000 mg, n = 10)

-0.91 (-17.99, 16.17)

20.25 (-18.25, 58.75)

21.16 (-21.07, 63.38)

0.318

 After Course 2 (≤1000 mg, n = 49; > 1000 mg, n = 4)

-14.74 (-33.14, 3.67)

-24.17 (-109.5, 61.17)

-9.44 (-96.73, 77.86)

0.828

  1. Data presented are LS mean (95% CI); a negative value indicates a decrease from baseline in the relevant parameter
  2. CI confidence interval, Hb haemoglobin, LS least squares, n number of patients with data, TSAT transferrin saturation